hVIVO (LON:HVO) Announces Earnings Results

hVIVO (LON:HVO) issued its earnings results on Tuesday. The company reported GBX (0.82) EPS for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 17.06% and a negative net margin of 12.48%.

hVIVO Price Performance

HVO stock traded down GBX 0.10 during trading on Friday, reaching GBX 5.90. 877,454 shares of the company were exchanged, compared to its average volume of 2,532,274. The company has a market cap of £40.62 million, a P/E ratio of -6.78 and a beta of 1.69. hVIVO has a 52-week low of GBX 4.30 and a 52-week high of GBX 11. The stock’s 50 day moving average price is GBX 6.76 and its 200 day moving average price is GBX 7.37. The company has a debt-to-equity ratio of 43.38, a quick ratio of 1.16 and a current ratio of 1.21.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.